Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M483Revenue $M36.3Net Margin (%)-1.2Altman Z-Score40.0
Enterprise Value $M363EPS $-0.0Operating Margin %-2.6Piotroski F-Score6
P/E(ttm)--Beneish M-Score22.9Pre-tax Margin (%)-1.2Higher ROA y-yY
Price/Book3.110-y EBITDA Growth Rate %-11.6Quick Ratio19.9Cash flow > EarningsY
Price/Sales12.75-y EBITDA Growth Rate %-25.8Current Ratio19.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-0.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-0.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M158ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GERN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
GERNFirst Eagle Investment 2015-06-30 Reduce-0.01%$3.62 - $4.33
$ 2.86-28%Reduce -77.40%164,700
GERNFirst Eagle Investment 2015-03-31 Reduce$2.81 - $4.34
$ 2.86-16%Reduce -35.43%728,866
GERNFirst Eagle Investment 2014-12-31 Reduce-0.01%$1.85 - $3.84
$ 2.863%Reduce -48.64%1,128,866
GERNFirst Eagle Investment 2014-09-30 Reduce-0.01%$2.12 - $3.014
$ 2.8616%Reduce -38.05%2,198,124
GERNFirst Eagle Investment 2014-03-31 Add0.01%$1.6 - $5.4
$ 2.86-29%Add 46.43%3,054,252
GERNFirst Eagle Investment 2013-03-31 Add$1.01 - $1.64
$ 2.86107%Add 36.91%2,410,934
GERNGeorge Soros 2011-03-31 Sold Out $4.44 - $5.07
$ 2.86-39%Sold Out0
GERNFirst Eagle Investment 2010-12-31 Add0.03%$4.46 - $6.02
$ 2.86-45%Add 74.80%2,570,500
GERNGeorge Soros 2010-12-31 Buy $4.46 - $6.02
$ 2.86-45%New holding26,500
GERNFirst Eagle Investment 2010-06-30 Add0.02%$4.67 - $5.81
$ 2.86-44%Add 77.56%1,420,500
GERNFirst Eagle Investment 2010-03-31 Add0.03%$4.97 - $6.21
$ 2.86-49%Add 204.80%800,000
GERNFirst Eagle Investment 2009-12-31 Add0.02%$4.91 - $6.69
$ 2.86-48%Add 556.18%262,471
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GERN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

GERN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRS MELISSA KELLYEVP BD and Port&Alliance Mgmt 2015-05-29Sell2,380$3.84-25.52view
Bloom Olivia KyusukEVP, CFO 2015-05-29Sell2,380$3.84-25.52view
Hofstaetter ThomasDirector 2015-03-18Sell70,000$4.1-30.24view
Bloom Olivia KyusukEVP, CFO 2014-05-29Sell3,379$2.136.19view
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt 2014-05-29Sell4,826$2.136.19view
BRADBURY DANIELDirector 2014-05-09Buy142,776$1.7563.43view
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt 2014-04-01Sell12,310$2.1334.27view
Bloom Olivia KyusukEVP, CFO 2014-04-01Sell7,435$2.1334.27view
SCARLETT JOHN APresident and CEO 2013-04-01Buy50,000$1.03177.67view
BEHRS MELISSA KELLYSVP Alliance and Prog Mgmt 2013-01-17Sell28,292$1.6573.33view

Quarterly/Annual Reports about GERN:

    News about GERN:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
    Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
    Geron: Buyer Beware Oct 13 2010 
    Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
    Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
    Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
    The Next Boom Emerges Nov 23 2008 

    More From Other Websites
    Biotechnology Stocks Technical Snapshot -- Geron, ACADIA Pharma, Alexion Pharma, and Illumina Feb 03 2016
    Endonovo Therapeutics Tops Our List For Investor Potential in Biotechs Jan 28 2016
    The Top 5 Health Care Penny Stocks for 2016 (CRIS, GERN) Jan 21 2016
    Geron Up, Myelodysplastic Syndromes Phase II/III Study Begins Jan 15 2016
    Geron Mixed After Company Announces Start Of Phase 2/3 Clinical Trial Jan 14 2016
    Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic... Jan 14 2016
    Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic... Jan 14 2016
    GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 11 2016
    Immigration Update | Philippines Jan 11 2016
    Today's Market Driven by Key Factors -- Research on Tumi Holdings, Meritor, Achillion... Dec 21 2015
    Geron Corp. Earnings Analysis: Q3, 2015 By the Numbers Dec 18 2015
    Traders Look to Upside - Free Research on Geron, MaxLinear, Halozyme Therapeutics and Viavi... Dec 10 2015
    GERON CORP Financials Dec 08 2015
    Piper Jaffray Sees Strength In Geron After News Of Drug Development Dec 07 2015
    'Mad Money' Lightning Round: Sell Chevron and Royal Dutch Shell Dec 05 2015
    Geron Announces December Conference Presentation Webcasts Nov 30 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)